Navigation Links
Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component

SAN DIEGO, April 13 /PRNewswire-USNewswire/ -- The Barbara Ann Karmanos Cancer Institute researchers today presented, at the American Association for Cancer Research annual meeting in San Diego, CA, the potential benefits of Thymoquinone (TQ), a compound present in the oil of black seeds (Nigella sativa), in treating pancreatic cancer.

(Logo: )

For centuries, these black seeds have been consumed in Asia, Africa and the Middle East to promote health and fight disease. TQ, an active component of the seeds, has been isolated for its promise as a chemopreventative agent. Pancreatic cancer cells currently have a high degree of inherent and acquired chemoresistance to standard chemotherapy agents Gemcitabine and/or Oxaliplatin, making these drugs only moderately effective.

"Our goal with this study was to increase the effectiveness of current pancreatic cancer treatments with a naturally occurring substance," said Sanjeev Banerjee, Ph.D., researcher, working under the leadership of Fazlul Sarkar, Ph.D., professor of pathology at the Karmanos Cancer Institute, Wayne State University. "We also explored the molecular mechanisms associated with TQ to promote better therapeutic outcomes."

Drs. Banerjee and Sarkar, along with Karmanos researchers Ramzi Mohammad, Ph.D. and Zhiwei Wang, Ph.D., pre-treated pancreatic tumor cells possessing different molecular signatures (HPAC, BxPC-3, Panc-1 and MDA Panc-28, COLO 357, L3.6pl), with TQ prior to administering Gemcitabine and Oxaliplatin. They found that TQ significantly enhanced the chemosensitivity of the tumor cells, making the Gemcitabine and Oxaliplatin agents more effective in treating the cancer. The TQ pre-treatment improved the drugs' effect on promoting cancer cell death and halting tumor cell growth.

Karmanos researchers also discovered at a molecular level, TQ down regulated the normally active NF-B transcription factor and several of its downstream effector genes responsible for metastasis and cell invasion. NF-B is involved in cellular responses to stimuli such as stress, free radicals, ultraviolet irradiation and bacterial or viral antigens. It also plays a key role in regulating the immune response to infection, and is instrumental in the development of many chronic diseases, including cancer. These results suggest that an important molecular target could be down regulated by TQ in reversing chemoresistance, as well as the inhibition of invasion and metastasis of pancreatic cancer.

Further research is currently underway at Karmanos to obtain better clues for TQ's efficacy in future Phase I/II clinical trials. Thus, the research team at Karmanos is actively collaborating with physicians both at the Karmanos Cancer Center and the MD Anderson Cancer Center in Houston, Texas for assessing the clinical utility of TQ.

About the Barbara Ann Karmanos Cancer Institute

Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 39 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute strives to prevent, detect and eradicate all forms of cancer. John C. Ruckdeschel, M.D., is the Institute's president and chief executive officer. For more information call 1-800-KARMANOS or go to

American Association for Cancer Research

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, AACR is the world's oldest and largest professional organization dedicated to advancing cancer research. The AACR Annual Meeting attracts more than 17,000 participants who share the latest discoveries and developments in the field.

SOURCE Karmanos Cancer Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. McCarty Cancer Foundation Awards $50,000 Grant for Myeloma Research Program at Karmanos Cancer Institute
2. Nominations for Outstanding Cancer Survivor Award Being Accepted by Karmanos Cancer Institute Through April 27
3. Kroger Pink Tag Campaign Raises $137,500 for Breast Cancer Research and Awareness at Karmanos Cancer Institute
4. Danialle Karmanos Work It Out Launches Dynamic Blog
5. Karmanos Cancer Center Most Preferred Hospital for Cancer Care According to 2007 Survey
6. Susan G. Komen For The Cure, Karmanos Cancer Institute, Local Hospitals Call on Policymakers to Address Injustice and Unfairness in Breast Cancer Incidence and Mortality
7. Susan G. Komen for the Cure, Karmanos Cancer Institute, Community Leaders, Breast Cancer Survivors and Activists to Gather at Forum and Call for Action on Breast Cancer
8. Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
9. Researchers find disparities in depression among older Hispanics in US
10. Researchers Identify New Genetic Links to Psoriasis
11. Penn researchers discover modus operandi of heart muscle protein
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the ... 2016 Building Better Radiology Marketing Programs meeting will showcase some of ... 6, 2016, at Caesars Palace in Las Vegas with a pre-conference session on ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... 2015 , ... Indosoft Inc., developer and distributor of the ... LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making the ... a version of Asterisk that will receive not only security fixes, but feature ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD ... for diagnostic imaging in the Waterloo region. Using the Ocean Platform, family physicians ... directly from their electronic medical record (EMR) without the need for redundant patient ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... Juntendo universitetssjukhus ser potential att använda ... magnetresonansbilder (MR-bilder) för patienter med multipel ... ett forskningsavtal med SyntheticMR AB för att ... forskningsprojekt på sjukhuset. Med SyMRI kan man ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: